7 news items
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GRTS
9 May 24
approach in infectious diseases. In February 2024, Gritstone announced that it plans to incorporate GMP-grade materials
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
GRTS
1 Apr 24
that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied
Gritstone bio Announces Proposed Public Offering
GRTS
1 Apr 24
, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
GRTS
1 Apr 24
for such data to change as more patient data become available and are subject to audit and verification procedures that could result in material changes
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
GRTS
5 Mar 24
-- -- Gritstone incorporating GMP-grade raw materials in the manufacture of its samRNA vaccine for COVID-19, preparing
i9jxx63lsyt5d0g2tom1q97ajh
ACIC
ADIL
ARVN
1 Mar 24
. (NASDAQ:NYCB) fell 24.2% to $3.6301 after the company identified material
8w4eeolg
AKAN
CRDF
DELL
1 Mar 24
. (NASDAQ:NYCB) fell 28% to $3.45 in pre-market trading after the company identified material weakness
- Prev
- 1
- Next